Cytori fully enrolls pivotal U.S. phase III scleroderma trial
Cytori announced that its U.S. FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrollment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017. May 25, 2016